{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:01:54Z","timestamp":1776650514047,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.leukres.2015.03.001","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T14:33:20Z","timestamp":1427639600000},"page":"801-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN"],"prefix":"10.1016","volume":"39","author":[{"given":"Alessandro","family":"Andriani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Villiv\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Andrizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"De Gregoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambra","family":"Di Veroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Maurillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2015.03.001_bib0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.leukres.2015.03.001_bib0080","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2015.03.001_bib0085","first-page":"S2","article-title":"Molecular mechanisms of tumor progression in chronic myeloproliferative disorders","volume":"8","author":"Gaidano","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL_myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2015.03.001_bib0095","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2015.03.001_bib0100","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.03.001_bib0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.leukres.2015.03.001_bib0110","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.26354","article-title":"Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program","volume":"118","author":"Maurillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2015.03.001_bib0115","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","article-title":"Azacitidine for the treatment of lower risk myelodysplastic syndromes","volume":"116","author":"Musto","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2015.03.001_bib0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.leukres.2015.03.001_bib0125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.03.001_bib0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/leu.2008.136","article-title":"5-Azacitidine has limited therapeutic activity in myelofibrosis","volume":"23","author":"Mesa","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.001_bib0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post essential thrombocytemia\/polycytemia vera myelofibrosis","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.001_bib0140","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression in Philadelphia-negative myeloproliferative neoplasms to myelodisplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on behalf og Groupe Francophone del Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T23:26:41Z","timestamp":1537745201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0145212615000703"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}